Federal Cannabis Status Unchanged Despite State-Level Reforms

Federal Classification Unchanged

Cannabis is classified as a Schedule I controlled substance under 21 U.S.C. § 812, the same category as heroin and LSD, with no accepted medical use recognized by the federal government. This classification hasn't budged since the Controlled Substances Act took effect in 1970. That's despite decades of state-level reform and mounting clinical evidence of therapeutic applications.

The Drug Enforcement Administration initiated a rescheduling review in August 2023 following a Department of Health and Human Services recommendation to move cannabis to Schedule III. That review remains pending as of May 25, 2026, with no final rule published in the Federal Register.

State-Federal Conflict Persists

Twenty-four states and the District of Columbia have legalized adult-use cannabis sales, while 38 states permit medical cannabis programs, creating direct conflict with federal prohibition. The mismatch exposes operators to federal prosecution and banking restrictions even when they're fully compliant with state law.

Key federal-state conflicts include:

• Federal banking prohibitions under the Bank Secrecy Act force most operators into cash-only business models
• IRS Code Section 280E denies standard business deductions for entities trafficking in Schedule I or II substances, imposing effective tax rates of 70% or higher
• Interstate commerce bans prevent legal operators from shipping product across state lines, even between two legal states
• Federal employment and housing protections don't extend to cannabis users, regardless of state law

Enforcement Posture Varies by Administration

Federal enforcement priorities have shifted with each administration, creating operational uncertainty for state-legal businesses. The Obama-era Cole Memo (2013) deprioritized enforcement in states with strong regulatory frameworks. The Trump administration rescinded that memo in 2018 but didn't significantly increase prosecutions. The Biden administration has largely maintained a hands-off posture toward state-legal operators while continuing enforcement against unlicensed activity.

No federal statute currently provides safe harbor for state-legal cannabis businesses. The SAFE Banking Act has passed the House seven times since 2019 but has never advanced in the Senate.

What This Means for Operators and Consumers

The federal-state split creates material legal and financial risk for every participant in state-legal markets. Operators face 280E tax burdens, banking blackouts, and the theoretical risk of federal asset forfeiture. Consumers in legal states can still be denied federal employment, housing, or firearms permits based on cannabis use. Medical patients using state-legal cannabis products have no federal workplace protections under the Americans with Disabilities Act.

For comprehensive background on the federal rescheduling process and its potential impact, see the CannIntel topic hub on federal cannabis legalization status.

The next signal: DEA is required under the Administrative Procedure Act to publish a notice of proposed rulemaking before any Schedule change takes effect. No such notice has been filed as of May 25, 2026.